Company intelligence / Profile preview

Mardil Medical

Minneapolis, Minnesota, United Statesmddionline.com ↗

Ownership: Private
Employees: ~3
Development stage: Phase 1

Overview

Mardil Medical developed the VenTouch System, an implantable device for minimally invasive repair of functional mitral regurgitation. The company completed first-in-human implants and reported positive interim pilot data in the late 2000s but appears to have ceased operations with no further clinical progress reported. The company raised approximately $25 million in funding before closing.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Implantable Medical Devices

Drug pipeline

1 asset

VenTouch

Phase 1

Indications: Functional Mitral Valve Regurgitation, Functional Tricuspid Valve Regurgitation

Beyond the preview

Go deeper on Mardil Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mardil Medical.

Explore the full profile